News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ArmaGen Technologies, Inc. Receives Notice Of Allowance For U.S. Patent Covering Novel Investigational Therapy For Hunter Syndrome


6/17/2014 10:15:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CALABASAS, Calif.--(BUSINESS WIRE)--ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders, announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent claiming the composition of AGT-182, a novel enzyme replacement therapy (ERT) under development for the treatment of neurological complications in patients with Hunter syndrome. The patent, when issued, will be in force until at least 2030.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES